Company Profile

Rejuvenate Bio Inc
Profile last edited on: 8/1/2019      CAGE: 7HSV8      UEI: GEKFSVSTKK55

Business Identifier: Novel Treatments for Mitral Valve Disease
Year Founded
2015
First Award
2017
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

235 Freeman Unit 3
Brookline, MA 02116
   (916) 396-3714
   N/A
   www.rejuvenatebio.com
Location: Single
Congr. District: 04
County: Suffolk

Public Profile

Rejuvenate Bio Inc. develops novel therapeutics for mitral valve disease. The firm is focused on gene therapies for dogs. Over seven million dogs in the United States alone have Mitral Valve Disease (MVD). For certain breeds, such as Cavalier King Charles Spaniels, more than 80% of dogs will be afflicted with MVD. The firm aims to change this via a cardio-protective gene therapy that holds the promise of stopping the progression of MVD.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 SOCOM $4,587,768
Project Title: Improving Human Performance through Neuroenhancement
2021 2 SOCOM $3,094,542
Project Title: Human Performance Optimization
2017 1 SOCOM $99,886
Project Title: Enhanced Canine Performance, Protection and Survivability

Key People / Management

  Daniel Oliver -- CEO and Founder

  Zergham Ahmed -- Intern

  Noah Davidsohn -- CSO and Founder

Company News

There are no news available.